Acute leukemia in adults: Novel allogeneic transplant strategies

Hematology

Volumn 17, Issue SUPPL. 1, 2012, Pages

  Lazarus, Hillard M ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Acute leukemia; Allogeneic hematopoietic cell transplantation; Treatment related mortality

Indexed keywords

BUSULFAN; CLOFARABINE; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; NOTCH RECEPTOR; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ALLOGRAFT; ALLOTRANSPLANTATION; ARTICLE; BONE MARROW; CANCER RADIOTHERAPY; CELL EXPANSION; DISEASE CONTROL; DONOR SELECTION; DRUG DOSE ESCALATION; EX VIVO STUDY; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; HUMAN; IMMUNOTHERAPY; LEUKEMIA REMISSION; MESENCHYMAL STROMA CELL; MORTALITY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; RECURRENCE FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REGULATORY T LYMPHOCYTE; RELAPSE; T CELL DEPLETION; T LYMPHOCYTE; TOMOTHERAPY; TREATMENT DURATION; TREATMENT OUTCOME; UMBILICAL CORD BLOOD; WHOLE BODY RADIATION;

ADULT; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84859771291     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13336169155493     Document Type: Article

References (19)

1. Ferrara JL, Anasetti C, Stadtmauer E, Antin J, Wingard J, Lee S, et al. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. Biol Blood Marrow Transplant. 2007;13(11):1268-85.
2. + T-cell response against the nonengrafted unit. Blood. 2010;115(4):757-65.
3. de Lima M, Robinson S, McMannis J, et al. Mesenchymal stem cell (MSC) based cord blood (CB) expansion (Exp) leads to rapid engraftment of platelets and neutrophils (abstract #362). Blood. 2010;116:362.
4. de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. BoneMarrow Transplant. 2008;41(9):771-8.
5. Delaney C, Ratajczak MZ, Laughlin MJ. Strategies to enhance umbilical cord blood stem cell engraftment in adult patients. Expert Rev Hematol. 2010;3(3):273-83.
6. Fuchs EJ, Huang XJ, Miller JS. HLA-haploidentical stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S57-63.
7. Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282-8.
8. Agura E, Berryman RB, Pineiro L, Vance E, Tadic-Ovcina M, Woelfel RG, et al. Preliminary results of phase II trial of clofarabine with parenteral busulfan (CLO/BU) followed by allogeneic related or unrelated donor transplantation for the treatment of hematologic malignancies (abstract #399). Biol Blood Marrow Transplant. 2011;17:S298-9.
9. Kirschbaum MH, Stein AS, Popplewell L, Delioukina M, Chen R, Nakamura R, et al. A phase I study in adults of clofarabine combined with high-dose melphalan as reduced intensity conditioning for allogeneic transplantation. Biol Blood Marrow Transplant. 2012;18(3):432-40.
10. Danylesko I, Shimoni A, Nagler A. Treosulfan-based conditioning before hematopoietic SCT: more than a BU lookalike. Bone Marrow Transplant. 2012;47(1):5-14.
11. Michallet M, Sobh M, Morisset S, Tedone N, Bay JO, Harousseau, JL, et al. Phase II prospective multicenter study of treosulfan based reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for hematological malignancies from 10/10 HLA identical unrelated donor. Biol Blood Marrow Transplant. 2011;17(2 Suppl):S285.
12. Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA, et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant. 2011;17(3):341-50.
13. Rosenthal J, Wong J, Stein A, Qian D, Hitt H, Naeem A, et al. Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies. Blood. 2011;117(1):309-15.
14. Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A, et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303. Biol Blood Marrow Transplant. 2011;17(9):1343-51.
15. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3):1061-70.
16. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921-8.
17. Lutz C, Massenkeil G, Nagy M, Neuburger S, Tamm I, Rosen O, et al. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(9):805-12.
18. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005;11(5):389-98.
19. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363(9419):1439-41.